Chaperon announced on the 13th that it will participate in 'Bio Europe Spring 2025' held in Europe to discuss the technology transfer of its next-generation atopic dermatitis treatment 'Nugel' with global bio companies. So far, meetings with more than 20 companies have been confirmed, including global companies.
'Bio Europe Spring 2025' will be held from the 17th to the 19th of this month in Milan, Italy. This event is an important occasion to promote strategic partnerships between the European and global life sciences industries. Last year, more than 3,000 companies from 61 countries and about 5,700 experts attended.
Participating companies include major pharmaceutical companies, life sciences-related firms, venture capital, and private equity firms, among various business leaders, providing opportunities to share the latest trends and collaborate through one-on-one meetings. Chaperon plans to focus on the technology transfer of Nugel, its self-developed atopic dermatitis treatment, at this conference.
A Chaperon official said, "Since European pharmaceutical companies are leading in the development of new drugs for atopic dermatitis treatment, participating in Bio Europe Spring 2025 will be a good opportunity for the technology transfer of Nugel," adding, "We are continuing close consultations such as data due diligence with several companies, so we expect visible results soon."
Nugel is the first atopic dermatitis treatment developed with a mechanism targeting the GPCR19 receptor to regulate inflammation. Unlike existing treatments, it controls both the initial and amplification stages of inflammation in innate immunity and also suppresses adaptive immune responses, enabling more effective and safer treatment, which is its distinguishing feature.
Nugel successfully completed the Phase 2b Part 1 clinical trial conducted by the U.S. FDA involving 33 multi-ethnic subjects. Based on the results of Part 1, Chaperon has started the Phase 2b Part 2 clinical trial with 177 multi-ethnic patients at four hospitals in Korea and eight hospitals in the U.S. Chaperon aims to complete dosing by December this year and secure the final clinical Phase 2 report in the first half of next year.
A Chaperon official emphasized, "Nugel has already proven superior safety and efficacy compared to existing competitive drugs through the Phase 2b Part 1 results," and added, "Based on the excellent clinical data derived from Part 1, we will accelerate technology transfer discussions with several global pharmaceutical companies."
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
